Stellar activation key free trial#

I have heard countless stories from patients about just how much this condition impacts their everyday lives socially, psychologically and physically. “Our hands are integral to everything we do. We are confident that with the DELTA FORCE study, delgocitinib cream may play a crucial role in expanding the options available for patients in this hard-to-treat condition,” said Kreesten Meldgaard Madsen, Chief Development Officer, LEO Pharma. “Currently, there is only one specific treatment option available for those living with severe CHE. No specific treatment-emergent safety concerns were identified for delgocitinib cream, and the overall safety profile was consistent with what was observed in DELTA 1, 2 and 3.

Stellar activation key free trial#

2 Delgocitinib cream is currently under investigation and is not yet approved for use by any health authority.ĭelgocitinib cream achieved the primary outcome measure of the trial by demonstrating a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules.ĭelgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, a reduction in HECSI score from baseline to Week 24, and a significant improvement in health-related quality of life (HRQoL), as measured by the Dermatology Life Quality Index (DLQI).įurthermore, patients receiving delgocitinib cream had a lower number of treatment-emergent adverse events (AEs) compared to those receiving alitretinoin capsules. 1 Alitretinoin is the only treatment currently approved to specifically treat severe CHE in patients who do not respond to topical corticosteroids. 1 It is a phase 3, two-arm trial (N=513) that compares the efficacy and safety of delgocitinib cream with alitretinoin capsules. LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the DELTA FORCE trial.ĭELTA FORCE is a head-to-head trial in adult participants with severe chronic hand eczema (CHE) comparing a potential new topical treatment with a systemic treatment.

With only one treatment option currently approved for severe CHE and no approved options for more moderate forms of the disease, there is a considerable unmet need for patients living with CHE. LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)ĭelgocitinib cream demonstrated a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules as its primary outcome measure.ĭelgocitinib cream also demonstrated superiority to alitretinoin capsules in all key secondary outcome measures, including Investigator’s Global Assessment (IGA)-CHE treatment success, health-related quality of life (HRQoL), and a lower number of treatment-emergent adverse events.ĭELTA FORCE is the first head-to-head phase 3 trial comparing a systemic and topical treatment for CHE.